Migratol
Generic Name
Migratine 200 mg
Manufacturer
Global Pharma Inc.
Country
USA
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| migratol 200 mg tablet | ৳ 10.00 | ৳ 100.00 |
Description
Overview of the medicine
Migratol 200 mg Tablet is a medication used for the acute treatment of migraine attacks with or without aura. It belongs to a class of drugs called triptans, which work by constricting blood vessels in the brain and relieving migraine symptoms like headache, nausea, and sensitivity to light and sound.
Uses & Indications
Dosage
Adults
Recommended initial dose is 200 mg at the onset of migraine symptoms. If symptoms return, a second dose may be taken after 2 hours. Maximum dose 400 mg in 24 hours.
Elderly
Use with caution in elderly patients, generally not recommended for those over 65 years due to increased risk of cardiovascular events.
Renal_impairment
No dose adjustment generally required for mild to moderate renal impairment. Use with caution in severe impairment.
How to Take
Oral administration. Swallow the tablet whole with water. Do not crush, chew, or split the tablet.
Mechanism of Action
Migratol is a selective agonist for 5-HT1B and 5-HT1D serotonin receptors. Activation of these receptors leads to cranial vasoconstriction and inhibition of inflammatory neuropeptide release from trigeminal nerve endings, thereby aborting migraine attacks.
Pharmacokinetics
Onset
30-60 minutes for headache relief.
Excretion
Mainly renal excretion, with a small amount excreted in feces.
Half life
Approximately 2-3 hours.
Absorption
Rapidly absorbed after oral administration; peak plasma concentrations reached within 1-2 hours.
Metabolism
Primarily hepatic metabolism via monoamine oxidase (MAO) A.
Side Effects
Contraindications
- Ischemic heart disease (e.g., angina pectoris, history of myocardial infarction)
- Cerebrovascular syndromes (e.g., stroke, transient ischemic attack)
- Peripheral vascular disease
- Uncontrolled hypertension
- Severe hepatic impairment
- Concurrent use with MAO inhibitors or within 2 weeks of discontinuing them
- Concurrent use with other 5-HT1 agonists or ergot-type medications
Drug Interactions
SSRIs/SNRIs
Increased risk of serotonin syndrome.
MAO Inhibitors
Increased plasma concentration of Migratol and risk of serotonin syndrome. Contraindicated.
Ergot alkaloids
Increased risk of prolonged vasospastic reactions. Contraindicated.
Other 5-HT1 agonists
Increased risk of vasospastic reactions. Contraindicated.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
Symptoms of overdose include severe vasoconstriction, hypertension, transient ischemic attacks, and other cardiovascular events. Management involves supportive therapy, monitoring of cardiovascular and respiratory function, and symptomatic treatment.
Pregnancy & Lactation
Pregnancy Category C. Use only if potential benefit justifies potential risk to the fetus. Small amounts may pass into breast milk; caution advised, consider discarding milk for 12-24 hours after dose.
Side Effects
Contraindications
- Ischemic heart disease (e.g., angina pectoris, history of myocardial infarction)
- Cerebrovascular syndromes (e.g., stroke, transient ischemic attack)
- Peripheral vascular disease
- Uncontrolled hypertension
- Severe hepatic impairment
- Concurrent use with MAO inhibitors or within 2 weeks of discontinuing them
- Concurrent use with other 5-HT1 agonists or ergot-type medications
Drug Interactions
SSRIs/SNRIs
Increased risk of serotonin syndrome.
MAO Inhibitors
Increased plasma concentration of Migratol and risk of serotonin syndrome. Contraindicated.
Ergot alkaloids
Increased risk of prolonged vasospastic reactions. Contraindicated.
Other 5-HT1 agonists
Increased risk of vasospastic reactions. Contraindicated.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
Symptoms of overdose include severe vasoconstriction, hypertension, transient ischemic attacks, and other cardiovascular events. Management involves supportive therapy, monitoring of cardiovascular and respiratory function, and symptomatic treatment.
Pregnancy & Lactation
Pregnancy Category C. Use only if potential benefit justifies potential risk to the fetus. Small amounts may pass into breast milk; caution advised, consider discarding milk for 12-24 hours after dose.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
36 months
Availability
Available in pharmacies and hospitals
Approval Status
Approved by major regulatory bodies (e.g., FDA, EMA)
Patent Status
Off-patent
Clinical Trials
Multiple phase III clinical trials demonstrated significant efficacy in reducing migraine pain and associated symptoms compared to placebo. Ongoing post-market surveillance studies.
Lab Monitoring
- No routine lab monitoring required. ECG may be considered in patients with risk factors for cardiovascular disease prior to first dose.
Doctor Notes
- Counsel patients on proper use for acute attacks only.
- Assess cardiovascular risk factors before prescribing.
- Advise against concomitant use with other triptans or ergotamines.
Patient Guidelines
- Take Migratol at the first sign of a migraine attack.
- Do not use for prevention of migraines.
- Do not exceed the recommended dose.
- Inform your doctor about all other medications you are taking.
Missed Dose Advice
Migratol is taken as needed for migraine attacks. There is no regular dosing schedule, so a missed dose is not applicable. Take a dose when a migraine attack starts.
Driving Precautions
May cause drowsiness or dizziness. Avoid driving or operating machinery if affected.
Lifestyle Advice
- Identify and avoid migraine triggers (e.g., certain foods, stress, lack of sleep).
- Maintain a regular sleep schedule.
- Stay hydrated and eat regular meals.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.